News
8h
Dealbreaker on MSNBioNTech to Pay $740M-Plus to Settle mRNA Patent Disputes, Smooth $1.25 Billion DealIn litigation over the past two years, CureVac alleged the BioNTech and Pfizer vaccine for Covid-19 infringed CureVac patents ...
CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...
GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...
Q1 2025 Management View CEO Matthew Gline described the quarter as "relatively quiet" ahead of an "exciting, busy fall," ...
NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...
Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage.
Kennedy is vowing to "fix" the federal program for compensating Americans injured by vaccines, opening the door to sweeping changes for a system long targeted by anti-vaccine activists.
This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results